US Moderna Therapeutics has announced the first positive results (in its first phase) of its experimental Covid-19 vaccine. Early findings from a first human trial of the vaccine suggest that it may create an immune response. The objective of the trial, conducted in only 45 people, was to test the safety of three doses with two injections. The firm plans to make a $1.3 Bn capital increase in order to finance the manufacturing process of this potential vaccine at a 5% discount vs yesterday’s close.